This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMagForce (MF6) 주식 개요Develops advanced nanomedicine for cancer therapies. 자세히 보기MF6 펀더멘털 분석스노우플레이크 점수가치 평가3/6미래 성장5/6과거 실적0/6재무 건전성0/6배당0/6강점공정 가치 추정치보다 낮은 96.6% 에서 거래수익은 매년 148.98% 증가할 것으로 예상됩니다.위험 분석의미 있는 시가총액이 없습니다(€4M)주식은 유동성이 매우 낮습니다의미 있는 수익이 없습니다(€1M)지난 1년 동안 주주가 희석되었습니다.모든 위험 점검 보기MF6 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.12해당 없음내재 할인율Est. Revenue$PastFuture-14m15m2016201920222025202620282031Revenue €8.4mEarnings €1.1mAdvancedSet Fair ValueView all narrativesMagForce AG 경쟁사AudientesSymbol: DB:AUGMarket cap: €6.9mGeratherm MedicalSymbol: XTRA:GMEMarket cap: €15.3maap ImplantateSymbol: XTRA:AAQ1Market cap: €27.1mPULSION Medical SystemsSymbol: MUN:PUSMarket cap: €178.1m가격 이력 및 성과MagForce 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가€0.1252주 최고가€3.5052주 최저가€0.11베타1.531개월 변동0%3개월 변동0%1년 변동-96.30%3년 변동-97.41%5년 변동-98.45%IPO 이후 변동-99.82%최근 뉴스 및 업데이트Reported Earnings • Jul 01Full year 2021 earnings: Revenues miss analyst expectationsFull year 2021 results: Net loss: €10.6m (down 172% from profit in FY 2020). Revenue missed analyst estimates by 94%. Over the next year, revenue is forecast to grow 823%, compared to a 7.5% growth forecast for the industry in Germany.Valuation Update With 7 Day Price Move • Jun 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to €1.94, the stock trades at a trailing P/E ratio of 3.9x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total loss to shareholders of 60% over the past three years.공시 • Jun 23MagForce AG, Annual General Meeting, Aug 31, 2022MagForce AG, Annual General Meeting, Aug 31, 2022.Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €1.87, the stock trades at a trailing P/E ratio of 3.8x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Total loss to shareholders of 60% over the past three years.Price Target Changed • Apr 27Price target decreased to €11.00Down from €11.86, the current price target is an average from 3 analysts. New target price is 393% above last closing price of €2.23. Stock is down 45% over the past year. The company is forecast to post a net loss per share of €0.14 compared to earnings per share of €0.50 last year.Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improved over the past weekAfter last week's 19% share price gain to €2.29, the stock trades at a trailing P/E ratio of 4.6x. Average forward P/E is 37x in the Medical Equipment industry in Germany. Total loss to shareholders of 53% over the past three years.더 많은 업데이트 보기Recent updatesReported Earnings • Jul 01Full year 2021 earnings: Revenues miss analyst expectationsFull year 2021 results: Net loss: €10.6m (down 172% from profit in FY 2020). Revenue missed analyst estimates by 94%. Over the next year, revenue is forecast to grow 823%, compared to a 7.5% growth forecast for the industry in Germany.Valuation Update With 7 Day Price Move • Jun 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to €1.94, the stock trades at a trailing P/E ratio of 3.9x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total loss to shareholders of 60% over the past three years.공시 • Jun 23MagForce AG, Annual General Meeting, Aug 31, 2022MagForce AG, Annual General Meeting, Aug 31, 2022.Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €1.87, the stock trades at a trailing P/E ratio of 3.8x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Total loss to shareholders of 60% over the past three years.Price Target Changed • Apr 27Price target decreased to €11.00Down from €11.86, the current price target is an average from 3 analysts. New target price is 393% above last closing price of €2.23. Stock is down 45% over the past year. The company is forecast to post a net loss per share of €0.14 compared to earnings per share of €0.50 last year.Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improved over the past weekAfter last week's 19% share price gain to €2.29, the stock trades at a trailing P/E ratio of 4.6x. Average forward P/E is 37x in the Medical Equipment industry in Germany. Total loss to shareholders of 53% over the past three years.Price Target Changed • Apr 02Price target decreased to €10.70Down from €11.86, the current price target is an average from 3 analysts. New target price is 453% above last closing price of €1.94. Stock is down 56% over the past year. The company is forecast to post a net loss per share of €0.14 compared to earnings per share of €0.50 last year.Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €1.75, the stock trades at a trailing P/E ratio of 3.5x. Average forward P/E is 33x in the Medical Equipment industry in Germany. Total loss to shareholders of 68% over the past three years.공시 • Feb 08+ 1 more updateMagForce AG to Report First Half, 2022 Results on Oct 27, 2022MagForce AG announced that they will report first half, 2022 results on Oct 27, 2022Reported Earnings • Nov 01First half 2021 earnings released: €0.17 loss per share (vs €0.18 loss in 1H 2020)First half 2021 results: Net loss: €5.05m (loss widened 3.6% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Major Estimate Revision • Jul 21Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from €3.50m to €2.03m. EPS estimate unchanged from -€0.19 per share at last update. Medical Equipment industry in Germany expected to see average net income growth of 7.4% next year. Consensus price target of €11.28 unchanged from last update. Share price was steady at €3.66 over the past week.Price Target Changed • Jun 29Price target decreased to €11.28Down from €12.65, the current price target is an average from 5 analysts. New target price is 186% above last closing price of €3.94. Stock is up 27% over the past year.공시 • Apr 26MagForce AG Announces Additional Supportive Data from Stage 2a of its Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy SystemMagForce AG together with its subsidiary MagForce USA, Inc. announced additional supportive data from Stage 2a of its pivotal U.S. study with the NanoTherm therapy system for the focal ablation of intermediate risk prostate cancer. Further analysis of the Stage 2a results confirmed the initial findings of a 10-patient cohort. Results showed that only the expected minimal treatment-related side effects, which are tolerable and similar to those observed in Stage 1 with an accelerated procedure, could be maintained in the streamlined procedure. The favorable safety and tolerability profile demonstrated in Stage 1 was also confirmed. Upon FDA approval, this streamlined procedure will allow patient treatment to be completed within a single day. Results of focal treatment effectivity remain extremely reassuring. Ablation-analysis furthermore showed well-defined ablation and cell death in the region of the nanoparticle deposit, with minimum tissue damage outside 2 to 4 mm from the deposit edge. It was once again confirmed that the newly developed minimally invasive procedure places the NanoTherm particles in a clinical targeted volume (CTV) of less than 2 to 4 cc of volume in the human prostate and provides for a focal ablation therapy. By modifying the thixotropic nature of the NanoTherm particles, an increase in viscosity of 100 times was achieved, which allowed NanoTherm to remain better at the reverse biopsy instillation site and provide time for the NanoTherm conjugation to occur, stabilizing the NanoTherm particles in the CTV. Compared to Stage 1, MagForce was able to improve the accuracy of instillation in Stage 2a to more than 90%, resulting in a greater NanoTherm particle mass in the targeted area. The findings show only minimal treatment-related side effects, which were tolerable and similar to those commonly associated with biopsies. To minimize discomfort during the 50 minute activation procedure, the patient cooling system was optimized based on the patient's size and weight. The clinical protocol for Stage 2b of the trial has been reviewed by the FDA and is actively recruiting patients while treatment effectiveness was evaluated in Stage 2a. Stage 2b will enroll up to 100 men in total. The study is expected to commence at MagForce's Focal Treatment Center in Texas, the centers in Florida and Washington will be subsequently included in the study. Although one study site would be sufficient to handle the required number of patients for the trial, MagForce will treat patients at all three of its U.S. sites in order to ensure that treatment centers are operational for commercialization once the clinical study is concluded.공시 • Feb 09MagForce AG Together with MagForce USA, Inc. Announce Patient Treatment in Stage 2A of Its Pivotal U.S. Study with the Nanotherm Therapy System for the Focal Ablation of Intermediate Risk Prostate Cancer Has Been CompletedMagForce AG together with MagForce USA, Inc., announces that patient treatment in Stage 2a of its pivotal U.S. study with the NanoTherm therapy system for the focal ablation of intermediate risk prostate cancer has been completed. Initial findings of Stage 2a showed in a 10-patients group that only the expected minimal treatment-related side effects, which are tolerable and similar to those observed in Stage 1 with an extended procedure, could be maintained in the streamlined procedure. The findings from Stage 1 demonstrated a favorable safety and tolerability profile as well as well-defined ablation and cell death in the region of the nanoparticle deposit. Upon FDA approval, this streamlined procedure will allow patient treatment to be completed within a single day. The next and final Stage 2b of the clinical trial is being initiated with MagForce's three Focal Treatment Centers in Texas, Washington and Florida. Stage 2b will focus on offering a treatment alternative to immediate risk prostrate cancer patients to that of definitive therapy. The purpose of this focal ablation registration study, which will enroll up to 120 men in a single arm study, is to demonstrate that the NanoTherm therapy system can focally ablate cancer lesions with minimal side effects for patients who have progressed to intermediate risk prostate cancer stage and are under active surveillance. By destroying these cancer lesions, it is anticipated that patients will be able to remain in Active Surveillance Programs and avoid definitive therapies such as surgery or whole gland radiation with their well-known side effects as long as possible. The American Society of Clinical Oncology reported in 2020 an estimated 191,930 new cases of prostate cancer in the United States. In spite of advances in diagnosis and treatment, an estimated 33,330 resulting deaths occurred. Clearly, early diagnosis and MagForce's focal therapy have a strong chance to reduce the death rate for prostate cancer. COVID-19 impact: While there are many restrictions that have been applied such as "Shelter at Home," exemptions exist for healthcare workers, such as MagForce's USA staff at the Company's clinical facilities. Clearly MagForce USA can conduct the trial in its out-patient facilities and has developed COVID-19 infection control protocols for staff and study subjects. These additional safety measures have caused a certain delay, but MagForce is hopeful that the next and final Stage of the clinical trial will not be unduly delayed since MagForce USA will conduct the trial from its own treatment centers.Is New 90 Day High Low • Dec 04New 90-day high: €4.98The company is up 87% from its price of €2.67 on 04 September 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €16.30 per share.분석 기사 • Dec 01Analysts Just Shaved Their MagForce AG (ETR:MF6) Forecasts DramaticallyToday is shaping up negative for MagForce AG ( ETR:MF6 ) shareholders, with the analysts delivering a substantial...Major Estimate Revision • Dec 01Analysts lower revenue estimates to €1.84mThe 2020 consensus revenue estimate decreased from €2.10m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -€0.21 to -€0.25 for the same period. The Medical Equipment industry in Germany is expected to see an average net income growth of 19% next year. The consensus price target of €11.86 was unchanged from the last update. Share price is up 38% to €4.38 over the past week.Is New 90 Day High Low • Nov 17New 90-day high: €3.02The company is up 2.0% from its price of €2.96 on 19 August 2020. The German market is also up 2.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €15.98 per share.Major Estimate Revision • Nov 04Analysts update estimatesThe 2020 consensus revenue estimate increased from €1.17m to €2.14m. Earning per share (EPS) estimate was unchanged from the last update at -€0.31. The Medical Equipment industry in Germany is expected to see an average net income growth of 18% next year. The consensus price target of €12.15 was unchanged from the last update. Share price stayed mostly flat at €2.37 over the past week.Is New 90 Day High Low • Sep 25New 90-day low: €2.45The company is down 20% from its price of €3.05 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €15.41 per share.주주 수익률MF6DE Medical EquipmentDE 시장7D0%2.3%2.8%1Y-96.3%-28.8%1.4%전체 주주 수익률 보기수익률 대 산업: MF6은 지난 1년 동안 -28.8%의 수익을 기록한 German Medical Equipment 산업보다 저조한 성과를 냈습니다.수익률 대 시장: MF6은 지난 1년 동안 1.4%를 기록한 German 시장보다 저조한 성과를 냈습니다.주가 변동성Is MF6's price volatile compared to industry and market?MF6 volatilityMF6 Average Weekly Movementn/aMedical Equipment Industry Average Movement6.1%Market Average Movement6.0%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.7%안정적인 주가: MF6는 지난 3개월 동안 German 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: Insufficient data to determine MF6의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트199733Ben Lippswww.magforce.de/더 보기MagForce AG 기초 지표 요약MagForce의 순이익과 매출은 시가총액과 어떻게 비교됩니까?MF6 기초 통계시가총액€3.56m순이익 (TTM)-€10.57m매출 (TTM)€1.08m3.3x주가매출비율(P/S)-0.3x주가수익비율(P/E)MF6는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표MF6 손익계산서 (TTM)매출€1.08m매출원가€918.75k총이익€158.39k기타 비용€10.73m순이익-€10.57m최근 보고된 실적Dec 31, 2021다음 실적 발표일해당 없음주당순이익(EPS)-0.35총이익률14.70%순이익률-981.70%부채/자본 비율95.5%MF6의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2022/11/08 17:40종가2022/08/11 00:00수익2021/12/31연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스MagForce AG는 5명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Thomas JonesBerenbergSusie JanaEdison Investment ResearchCosmin FilkerGBC AG2명의 분석가 더 보기
Reported Earnings • Jul 01Full year 2021 earnings: Revenues miss analyst expectationsFull year 2021 results: Net loss: €10.6m (down 172% from profit in FY 2020). Revenue missed analyst estimates by 94%. Over the next year, revenue is forecast to grow 823%, compared to a 7.5% growth forecast for the industry in Germany.
Valuation Update With 7 Day Price Move • Jun 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to €1.94, the stock trades at a trailing P/E ratio of 3.9x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total loss to shareholders of 60% over the past three years.
공시 • Jun 23MagForce AG, Annual General Meeting, Aug 31, 2022MagForce AG, Annual General Meeting, Aug 31, 2022.
Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €1.87, the stock trades at a trailing P/E ratio of 3.8x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Total loss to shareholders of 60% over the past three years.
Price Target Changed • Apr 27Price target decreased to €11.00Down from €11.86, the current price target is an average from 3 analysts. New target price is 393% above last closing price of €2.23. Stock is down 45% over the past year. The company is forecast to post a net loss per share of €0.14 compared to earnings per share of €0.50 last year.
Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improved over the past weekAfter last week's 19% share price gain to €2.29, the stock trades at a trailing P/E ratio of 4.6x. Average forward P/E is 37x in the Medical Equipment industry in Germany. Total loss to shareholders of 53% over the past three years.
Reported Earnings • Jul 01Full year 2021 earnings: Revenues miss analyst expectationsFull year 2021 results: Net loss: €10.6m (down 172% from profit in FY 2020). Revenue missed analyst estimates by 94%. Over the next year, revenue is forecast to grow 823%, compared to a 7.5% growth forecast for the industry in Germany.
Valuation Update With 7 Day Price Move • Jun 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to €1.94, the stock trades at a trailing P/E ratio of 3.9x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total loss to shareholders of 60% over the past three years.
공시 • Jun 23MagForce AG, Annual General Meeting, Aug 31, 2022MagForce AG, Annual General Meeting, Aug 31, 2022.
Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €1.87, the stock trades at a trailing P/E ratio of 3.8x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Total loss to shareholders of 60% over the past three years.
Price Target Changed • Apr 27Price target decreased to €11.00Down from €11.86, the current price target is an average from 3 analysts. New target price is 393% above last closing price of €2.23. Stock is down 45% over the past year. The company is forecast to post a net loss per share of €0.14 compared to earnings per share of €0.50 last year.
Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improved over the past weekAfter last week's 19% share price gain to €2.29, the stock trades at a trailing P/E ratio of 4.6x. Average forward P/E is 37x in the Medical Equipment industry in Germany. Total loss to shareholders of 53% over the past three years.
Price Target Changed • Apr 02Price target decreased to €10.70Down from €11.86, the current price target is an average from 3 analysts. New target price is 453% above last closing price of €1.94. Stock is down 56% over the past year. The company is forecast to post a net loss per share of €0.14 compared to earnings per share of €0.50 last year.
Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €1.75, the stock trades at a trailing P/E ratio of 3.5x. Average forward P/E is 33x in the Medical Equipment industry in Germany. Total loss to shareholders of 68% over the past three years.
공시 • Feb 08+ 1 more updateMagForce AG to Report First Half, 2022 Results on Oct 27, 2022MagForce AG announced that they will report first half, 2022 results on Oct 27, 2022
Reported Earnings • Nov 01First half 2021 earnings released: €0.17 loss per share (vs €0.18 loss in 1H 2020)First half 2021 results: Net loss: €5.05m (loss widened 3.6% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Jul 21Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from €3.50m to €2.03m. EPS estimate unchanged from -€0.19 per share at last update. Medical Equipment industry in Germany expected to see average net income growth of 7.4% next year. Consensus price target of €11.28 unchanged from last update. Share price was steady at €3.66 over the past week.
Price Target Changed • Jun 29Price target decreased to €11.28Down from €12.65, the current price target is an average from 5 analysts. New target price is 186% above last closing price of €3.94. Stock is up 27% over the past year.
공시 • Apr 26MagForce AG Announces Additional Supportive Data from Stage 2a of its Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy SystemMagForce AG together with its subsidiary MagForce USA, Inc. announced additional supportive data from Stage 2a of its pivotal U.S. study with the NanoTherm therapy system for the focal ablation of intermediate risk prostate cancer. Further analysis of the Stage 2a results confirmed the initial findings of a 10-patient cohort. Results showed that only the expected minimal treatment-related side effects, which are tolerable and similar to those observed in Stage 1 with an accelerated procedure, could be maintained in the streamlined procedure. The favorable safety and tolerability profile demonstrated in Stage 1 was also confirmed. Upon FDA approval, this streamlined procedure will allow patient treatment to be completed within a single day. Results of focal treatment effectivity remain extremely reassuring. Ablation-analysis furthermore showed well-defined ablation and cell death in the region of the nanoparticle deposit, with minimum tissue damage outside 2 to 4 mm from the deposit edge. It was once again confirmed that the newly developed minimally invasive procedure places the NanoTherm particles in a clinical targeted volume (CTV) of less than 2 to 4 cc of volume in the human prostate and provides for a focal ablation therapy. By modifying the thixotropic nature of the NanoTherm particles, an increase in viscosity of 100 times was achieved, which allowed NanoTherm to remain better at the reverse biopsy instillation site and provide time for the NanoTherm conjugation to occur, stabilizing the NanoTherm particles in the CTV. Compared to Stage 1, MagForce was able to improve the accuracy of instillation in Stage 2a to more than 90%, resulting in a greater NanoTherm particle mass in the targeted area. The findings show only minimal treatment-related side effects, which were tolerable and similar to those commonly associated with biopsies. To minimize discomfort during the 50 minute activation procedure, the patient cooling system was optimized based on the patient's size and weight. The clinical protocol for Stage 2b of the trial has been reviewed by the FDA and is actively recruiting patients while treatment effectiveness was evaluated in Stage 2a. Stage 2b will enroll up to 100 men in total. The study is expected to commence at MagForce's Focal Treatment Center in Texas, the centers in Florida and Washington will be subsequently included in the study. Although one study site would be sufficient to handle the required number of patients for the trial, MagForce will treat patients at all three of its U.S. sites in order to ensure that treatment centers are operational for commercialization once the clinical study is concluded.
공시 • Feb 09MagForce AG Together with MagForce USA, Inc. Announce Patient Treatment in Stage 2A of Its Pivotal U.S. Study with the Nanotherm Therapy System for the Focal Ablation of Intermediate Risk Prostate Cancer Has Been CompletedMagForce AG together with MagForce USA, Inc., announces that patient treatment in Stage 2a of its pivotal U.S. study with the NanoTherm therapy system for the focal ablation of intermediate risk prostate cancer has been completed. Initial findings of Stage 2a showed in a 10-patients group that only the expected minimal treatment-related side effects, which are tolerable and similar to those observed in Stage 1 with an extended procedure, could be maintained in the streamlined procedure. The findings from Stage 1 demonstrated a favorable safety and tolerability profile as well as well-defined ablation and cell death in the region of the nanoparticle deposit. Upon FDA approval, this streamlined procedure will allow patient treatment to be completed within a single day. The next and final Stage 2b of the clinical trial is being initiated with MagForce's three Focal Treatment Centers in Texas, Washington and Florida. Stage 2b will focus on offering a treatment alternative to immediate risk prostrate cancer patients to that of definitive therapy. The purpose of this focal ablation registration study, which will enroll up to 120 men in a single arm study, is to demonstrate that the NanoTherm therapy system can focally ablate cancer lesions with minimal side effects for patients who have progressed to intermediate risk prostate cancer stage and are under active surveillance. By destroying these cancer lesions, it is anticipated that patients will be able to remain in Active Surveillance Programs and avoid definitive therapies such as surgery or whole gland radiation with their well-known side effects as long as possible. The American Society of Clinical Oncology reported in 2020 an estimated 191,930 new cases of prostate cancer in the United States. In spite of advances in diagnosis and treatment, an estimated 33,330 resulting deaths occurred. Clearly, early diagnosis and MagForce's focal therapy have a strong chance to reduce the death rate for prostate cancer. COVID-19 impact: While there are many restrictions that have been applied such as "Shelter at Home," exemptions exist for healthcare workers, such as MagForce's USA staff at the Company's clinical facilities. Clearly MagForce USA can conduct the trial in its out-patient facilities and has developed COVID-19 infection control protocols for staff and study subjects. These additional safety measures have caused a certain delay, but MagForce is hopeful that the next and final Stage of the clinical trial will not be unduly delayed since MagForce USA will conduct the trial from its own treatment centers.
Is New 90 Day High Low • Dec 04New 90-day high: €4.98The company is up 87% from its price of €2.67 on 04 September 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €16.30 per share.
분석 기사 • Dec 01Analysts Just Shaved Their MagForce AG (ETR:MF6) Forecasts DramaticallyToday is shaping up negative for MagForce AG ( ETR:MF6 ) shareholders, with the analysts delivering a substantial...
Major Estimate Revision • Dec 01Analysts lower revenue estimates to €1.84mThe 2020 consensus revenue estimate decreased from €2.10m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -€0.21 to -€0.25 for the same period. The Medical Equipment industry in Germany is expected to see an average net income growth of 19% next year. The consensus price target of €11.86 was unchanged from the last update. Share price is up 38% to €4.38 over the past week.
Is New 90 Day High Low • Nov 17New 90-day high: €3.02The company is up 2.0% from its price of €2.96 on 19 August 2020. The German market is also up 2.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €15.98 per share.
Major Estimate Revision • Nov 04Analysts update estimatesThe 2020 consensus revenue estimate increased from €1.17m to €2.14m. Earning per share (EPS) estimate was unchanged from the last update at -€0.31. The Medical Equipment industry in Germany is expected to see an average net income growth of 18% next year. The consensus price target of €12.15 was unchanged from the last update. Share price stayed mostly flat at €2.37 over the past week.
Is New 90 Day High Low • Sep 25New 90-day low: €2.45The company is down 20% from its price of €3.05 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €15.41 per share.
